Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Page 1
HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.
Ferrando-Martinez S, Huang K, Bennett AS, Sterba P, Yu L, Suzich JA, Janssen HLA, Robbins SH. Ferrando-Martinez S, et al. Among authors: suzich ja. JHEP Rep. 2019 Jun 28;1(3):170-178. doi: 10.1016/j.jhepr.2019.06.001. eCollection 2019 Sep. JHEP Rep. 2019. PMID: 32039367 Free PMC article.
The upregulation was maximal in HBV e antigen (HBeAg)-positive patients but persisted after HBeAg negativization and was not restored by long-term treatment. HBV reactivity, measured as frequency of HBV-specific T cells, was significantly higher in HBeAg-negative patients …
The upregulation was maximal in HBV e antigen (HBeAg)-positive patients but persisted after HBeAg negativization and was not restored by lon …
Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP; Motavizumab Study Group. Ramilo O, et al. Among authors: suzich j. Pediatr Infect Dis J. 2014 Jul;33(7):703-9. doi: 10.1097/INF.0000000000000240. Pediatr Infect Dis J. 2014. PMID: 24356256 Clinical Trial.
BACKGROUND: This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal antibody, would decrease viral load and improve clinical outcomes in previously healthy term infants hospitalized with RSV lower respi …
BACKGROUND: This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal a …
Respiratory syncytial virus infection is associated with an altered innate immunity and a heightened pro-inflammatory response in the lungs of preterm lambs.
Sow FB, Gallup JM, Krishnan S, Patera AC, Suzich J, Ackermann MR. Sow FB, et al. Among authors: suzich j. Respir Res. 2011 Aug 9;12(1):106. doi: 10.1186/1465-9921-12-106. Respir Res. 2011. PMID: 21827668 Free PMC article.
Previously, our laboratory demonstrated that preterm lambs had elevated viral antigen and developed more severe lesions compared to full-term lambs at seven days post-infection. Here, we compared the pathogenesis and immunological response to RSV infection in lungs of pret …
Previously, our laboratory demonstrated that preterm lambs had elevated viral antigen and developed more severe lesions compared to full- …
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA. Giannini SL, et al. Among authors: suzich j. Vaccine. 2006 Aug 14;24(33-34):5937-49. doi: 10.1016/j.vaccine.2006.06.005. Epub 2006 Jun 19. Vaccine. 2006. PMID: 16828940
An effective virus-like particle (VLP) based prophylactic vaccine designed to protect against persistent infection with human papillomavirus (HPV) types 16 and 18 and subsequent lesion development will need to induce a strong humoral and cellular immune response capable of provid …
An effective virus-like particle (VLP) based prophylactic vaccine designed to protect against persistent infection with human papillomavirus …
Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.
McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA. McCarthy MP, et al. Among authors: suzich ja. J Virol. 1998 Jan;72(1):32-41. doi: 10.1128/JVI.72.1.32-41.1998. J Virol. 1998. PMID: 9420197 Free PMC article.
We have determined conditions for the quantitative disassembly of purified HPV-11 L1 VLPs to the level of capsomeres, demonstrating that disulfide bonds alone are essential to maintaining long-term HPV-11 L1 VLP structure at physiological ionic strength. The ionic strength …
We have determined conditions for the quantitative disassembly of purified HPV-11 L1 VLPs to the level of capsomeres, demonstrating that dis …